Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tislelizumab - BeiGene

Drug Profile

Tislelizumab - BeiGene

Alternative Names: BGB-A317; TEVIMBRA; Tilelizumab; Tirelizumab - BeiGene; Tizveni; VDT-482

Latest Information Update: 30 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer Asieris Pharmaceuticals; BeiGene; Celgene Corporation; HUTCHMED; Leap Therapeutics; Novartis; Tianjin Medical University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Squamous cell cancer; Nasopharyngeal cancer; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hodgkin's disease; Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Registered Gastric cancer; Nasopharyngeal cancer
  • Preregistration Oesophageal cancer; Small cell lung cancer
  • Phase III Cancer
  • Phase II Bladder cancer; Cervical cancer; Colorectal cancer; Lung cancer; Lymphoma; Rectal cancer
  • Phase I/II Endometrial cancer; Haematological malignancies; Triple negative breast cancer
  • No development reported Ovarian cancer; Renal cancer

Most Recent Events

  • 23 Apr 2024 Registered for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, First-line therapy, Combination therapy) in Norway, Liechtenstein, Iceland, European Union (IV)
  • 23 Apr 2024 Registered for Non-small cell lung cancer (Second-line therapy or greater, Metastatic disease, Monotherapy, Late-stage disease) in Norway, Liechtenstein, Iceland, European Union (IV)
  • 23 Apr 2024 Registered for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Iceland, Norway, Liechtenstein, European Union (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top